PluroGel
Phase 2Small molecule
PluroGel is one of 31 small molecule programs targeting Burn. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
30 competitors in Burn
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Zyvox
PfizerApproved
Calciferol
Jazz PharmaceuticalsApproved
Dobutrex
Eli LillyApproved
Glucophage
EMD SeronoApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Cubicin
BBaxter Healthcare Corporation
Approved
Mycostatin
GGood Molecules, LLC
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PluroGel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPluroGen Therapeutics, Inc